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a b s t r a c t
Purpose: To report on the ‘‘Dutch Quality Improvement Project” regarding external beam (EBRT) and
brachytherapy (BT) contouring and treatment planning for locally advanced cervical cancer (LACC).
Material and methods: Two rounds of three workshops were organized. Data from two patients with LACC
were made available for homework exercises. Contouring and treatment planning was asked for accord-
ing to the EMBRACE-II protocol. The submissions were analysed and the results were addressed during
the workshops.
Results: Almost all invited centres participated. EBRT contouring guidelines were followed within accept-
able range, with major effort needed with regard to the ITV concept. BT contouring was of good quality,
with especially small discrepancies for centres already participating in EMBRACE.
EBRT treatment planning results improved between workshops with more centres being able to fulfil
the planning aims. Guidance was especially necessary to improve the coverage probability planning for
affected nodes.
For BT planning prioritizing between target coverage and OAR sparing improved over time; the varia-
tion in dose to vaginal points remained considerable, as did variation in loading patterns and spatial dose
distribution.
The project was highly appreciated by all participants.
Conclusion: Homework and workshop activities provide a suitable platform for discussion, exchange of
experience and improvement of quality and conformity. Due to this project, radiotherapy for LACC can
be administered with better and more comparable quality throughout the Netherlands.
 2018 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy &
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
Introduction
The Dutch Society of Radiation Oncology established a Platform
for Radiotherapy of Gynaecological Tumours (LPRGT) with mem-
bers from all radiation oncology centres that treat patients with
gynaecological tumours. The platform has a long standing experi-
ence in driving clinical multicentre studies like the PORTEC trials
for endometrial cancer [1–3]. Additionally, the LPRGT is actively
driving forward the clinical implementations of innovative tech-
nology. For locally advanced cervix cancer (LACC) brachytherapy
is applied according to GEC-ESTRO recommendations [4,5]. Con-
cerning developments for external beam radiotherapy treatment
(EBRT), the LPRGT adheres to contouring and planning as described
in the EMBRACE-II protocol (embracestudy.dk). This protocol
describes the current state-of-the-art (chemo)radiation and
brachytherapy (BT), based on the results of RetroEMBRACE and
EMBRACE-I studies, and other recent publications [6–13]. Impor-
tant aspects are the use of MRI information for EBRT and BT plan-
ning, intensity modulated radiotherapy (IMRT), simultaneously
integrated boosts (SIB) with coverage probability planning for the
treatment of regional lymph node metastases, daily image guided
radiotherapy, and MRI guided adaptive brachytherapy (IGABT).
https://doi.org/10.1016/j.tipsro.2018.10.001
2405-6324/ 2018 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy & Oncology.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The fast developments of image-guided adaptive treatment of
LACC induces changing ‘Patterns of care’ [14–18]. The importance
of training, audits, and continuous education is widely recognized,
and sharing experiences (joys and pitfalls) for chosen approaches
can boost clinical implementation.
The LPRGT initiated a ‘‘Dutch Quality Improvement Project” to
support the clinical implementation of state-of-the-art radiother-
apy and to strengthen national collaboration. It consisted of con-
touring and treatment planning exercises and workshops for
both EBRT and BT. The target audience consisted of teams of Radi-
ation Oncologists (RO), Medical Physicists (MP) and Radiation
Therapists (RTT). The aim of this paper is to report on this project,
including the achievements in EBRT and BT contouring and treat-
ment planning as well as organisational aspects.
Materials & methods
Organisation
The project group consisted of 3 RO and 3 MP from 4 centres
and was initiated by Dutch members of the EMBRACE-II study core
group. Fifteen of the 16 centres currently treating LACC patients
with EBRT participated and all (11) BT centres. The contouring
workshops aimed at ROs, the EBRT planning workshops were
meant for MPs and RTTs, and the BT planning workshops for teams
of ROs, MPs and RTTs.
A general invitation to participate in the programwas sent to all
16 centres in the summer of 2015. The first series of homework
exercises and full-day workshops was organized between October
2015 and March 2016. The number of participants for each work-
shop was limited to 30–40 persons, preferably in teams of 2 or 3
members per centre. The homework exercises were mandatory
for participation in the workshops. The tasks were meant to evalu-
ate the understanding of contouring and treatment planning prin-
ciples and served as a basis for discussing agreements and
discrepancies.
A second series of homework exercises and 3 half-day work-
shops were arranged between January and March 2017, in which
the same cases were used. Preparation was less labour intensive,
as the relevant data (images, contours) were already available at
the centres.
The project was funded by the Quality Project Program of the
Dutch Society of Radiation Oncology, and supported by Elekta
Brachytherapy (Veenendaal, The Netherlands).
Patient data
External beam case
For the EBRT case we used data of a 41 year old patient with
stage Ib2 squamous cell cancer and two pathological nodes in
the right pelvis, a single node in the left pelvis, and two nodes left
and right in the common iliac region. Reference contours for tar-
gets and OAR were created by two expert ROs.
Brachytherapy case
For the BT case we used data of a 59 year old patient with stage
IIb squamous cell cancer with involvement of the proximal 20 mm
of vagina, both parametria and uterine corpus. The patient received
two BT applications (with 2 HDR fractions each) with the Utrecht
applicator (Elekta, Veenendaal, Netherlands), the first with 3 inter-
stitial needles, and the second with 4 interstitial needles. Data of
the first application was used. The reference contours were gener-
ated by the same experts.
Data handling and homework exercises.
All imaging data were anonymised and sent in DICOM format to
the participants for importation into their local contouring and
planning software. Both patients had given informed consent for
using their data for educational purposes. Additionally, we sent a
set of instructions for the exercises as well as the relevant chapters
from the EMBRACE-II protocol, clinical information of the cases
and a digital form to report contouring/planning parameters.
Contouring for EBRT and BT
Seven weeks before the workshop, the images were transferred:
for EBRT, CT, PET and diagnostic MR scans, along with the registra-
tion between CT and MR; for BT, three T2w (axial, sagittal, coronal)
MR data sets. Contouring of the following target and organ at risk
(OAR) structures was asked for the EBRT case: GTV-Tinit, CTV-T-
HRinit, CTV-T-LRinit, ITV-T-LRinit (standard margin approach
EMBRACE II protocol), CTV-E, ITV45, PTV45, for each of the 5 sep-
arate nodes GTV-N, CTV-N, and PTV-N, as well as bladder, rectum,
sigmoid, and bowel ([19] and Appendix A). For the BT case, con-
tours of the GTVres, CTVHR, and CTVIR [4,19] were requested. DICOM
structure sets and volumes as calculated by the centre were to be
returned.
EBRT planning
After the contouring workshop, the reference contours for tar-
gets and OAR were distributed for both EBRT and BT planning exer-
cises. The assignment was to generate an IMRT or VMAT
(Volumetric Arc Therapy) plan, including a SIB for the 5 lymph
nodes, with aims and constraints based on the EMBRACE II proto-
col: 45 Gy to the elective PTV; and 55 Gy and 57.5 Gy to the nodes
(depending on the position), in 25 fractions. The planning aim, new
in EMBRACE II, was that the volume of PTV45 receiving 95% of the
planning aim dose (PTV45 V95%) should be higher than 95% (hard
constraint) but close to 95% (soft constraint, see Table 3 in [13]).
With respect to affected lymph nodes the concept of coverage
probability (CoP) planning was introduced [12], including the three
hard constraints (CTV-N D98 > 100%, PTV-N D98 > 90%,
Dmax < 107%) and one soft constraint (CTV-N D50 > 102%). The
dose distribution (in DICOM), the relevant DVH parameters, speci-
fic parameters of the planning technique and preferably results of
in-house plan QA measurements were to be returned.
BT planning
For the BT planning, an Oncentra Brachy (Elekta, Veenendaal,
Netherlands) RTplan file with applicator reconstruction was pro-
vided allowing all participants to use the same applicator recon-
struction and thereby facilitating a fair plan comparison. All
participants except one used Oncentra Brachy in their clinic.
The following dose points were to be placed: points A, ICRU
bladder, Lateral Vaginal points at 5 mm, and Recto-Vaginal Refer-
ence Point (RVRP) [19,20]. Three plans were required: (1) a generic
‘‘standard plan”, consisting of a set of pre-determined dwell times
and positions, (2) a centre-specific ‘‘centre standard plan” (not
optimized), and (3) an optimized plan according to the aims and
constraints of the EMBRACE-II protocol. DVH parameters for all
plans, DICOM RTdose and RTplan for the optimized plan were
returned. For the second workshop the coordinates of the dose
points were distributed and only an optimized plan was requested.
Analysis
For visualization, sanity checks and further evaluation, all
DICOM objects were centrally collected. All contours were dis-
played simultaneously to assess the location of delineation varia-
tions. The EBRT planning DVH parameters and compliance with
aims and constraints were evaluated. For BT, DVH parameters
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and doses to points were evaluated, as well as the contribution of
the different applicator components.
The workshops
Participation was accredited for all disciplines by their profes-
sional societies. The contouring- and brachy planning workshops
were organised at a location with 12 workstations.
A major part of each workshop was in-depth explanation of the
concepts, followed by a summary of results and feedback of the
exercises, especially focussing on discrepancies and errors.
For the contour workshop, standard ITV-T-LRinit pre-workshop
contours with isotropic margins were discussed and the difference
with respect to ITV-T-LRinit with individualized margins based on
the anatomy changes as found at different imaging time points
was highlighted. The participants practised live contouring, based
on MRI, CT and PET-CT information with different fillings of blad-
der and rectum.
Furthermore, the participants contributed with short presenta-
tions on various subjects: the patterns-of-care study in the Nether-
lands [15], the use of ‘library of plans’/’plan of the day’ approaches
for EBRT, and practical workflows for brachy treatment. There was
ample time for discussion and exchange of tips and tricks. Partici-
pants were asked to fill in evaluation sheets.
Results
Contouring
Thirty participants from 14 centres attended the first workshop,
13 centres sent in delineations for EBRT. Five centres contoured on
MRI, whereas eight still on CT, according to their clinical practice.
MRI derived target volumes were overall smaller with less varia-
tion (Fig. 1). The mean volumes of GTV-T and CTV-T-LRinit were
64 (SD 6)/198 (SD 20) cm3 on MRI and 93 (SD23)/280 (SD 36)
cm3 on CT, respectively. Contouring discrepancies for CTV-T-LRinit
were mainly in the parametria, cranially (peritoneal border), later-
ally (border obturator lymph node region) and caudally (parame-
tria to paracolpia). Additionally, several centres did not
accomplish the upper border of the lymphatic region according
to the pre-defined risk profile. Additionally, the extent of contours
varied especially around the aorta and vena cava, the caudal border
of the pre-sacral space, the caudal expansion of external iliac ves-
sels and obturator region. BT contouring was done by 10 of the 11
participating BT centres. Agreement for the target contours was
quite good; however there was a clear difference between the 5
centres already participating in the EMBRACE-I study versus the
others. The former generated smaller GTVres (mean 15 (SD 19) ver-
sus 22 (SD 42) cm3), larger CTVHR (mean 45 (SD 16) versus 39 (SD
26) cm3) with less variation. Discrepancies were mainly present for
remaining cervix and vaginal extension (Fig. S1).
Supplementary data associated with this article can be found, in
the online version, at https://doi.org/10.1016/j.tipsro.2018.10.001.
In the second contouring workshop a new group of ROs was
trained, from 10 centres. Overall the results were quite comparable
with the ones from the first workshop with slight improvement for
the ITV-T-LR concept.
EBRT planning
The first EBRT planning workshop had 31 participants (MPs and
RTTs) from 14 centres. Three (step and shoot) IMRT, 11 VMAT and
1 Tomotherapy plan were submitted. None of these 15 plans
met all 36 soft and hard dose constraints. Two plans were incor-
rect, the centres decided for field borders not fitting the (given)
PTV45: for centre C5 too high, for C11 too low. In 5 plans, the con-
straints for 32 parameters or more were achieved; three plans met
23 or more of 25 hard dose constraints. Problematic parameters
were minimum dose to ITV45 (9/15 violations), maximum dose
to bladder (10/15 violations) and bowel (7/15 violations). The max-
imum dose value allowed within 10 mm from the CTV-T-HRinit
(dose region of brachytherapy) was exceeded in all plans, due to
the proximity of a pelvic node which needed boosting. The median
PTV45 V95% was 98.4% (range 97–100%, Fig. 2), excluding the data
from the incorrect plans. The average PTV45 dose conformity
(V43Gy/PTV45) was 1.19 (SD 0.09) for 13 plans.
For the second workshop 10 plans were submitted. Two
met = 32 of 36 constraints. The ITV45 minimum dose constraint
was achieved in 7 of the 10 plans, an improvement over the first
round. Results for PTV45 V95% improved to median 96.5% (range
95.0 – 99.7%) (Fig. 2).
A direct comparison of PTV V95% for the 6 centres that provided
2 plans (C1, C2, C4, C6, C7, C8) between the first and second was
average 98% (SD 1.2%) and 96.4% (SD 1.3%), respectively.
With respect to CoP planning for affected lymph nodes, in the
first workshop 7/15 plans met all nodal criteria, 13 showed a max-
imum of 3 violations. In the second, 5/10 were flawless and 7
showed a maximum of 3 violations. A considerable variation in
dose distribution is possible, while still all nodal planning criteria
were fulfilled. For example Fig. S2 shows in one case a body
V50Gy = 86 cm3 and in the other 313 cm3, while both were meet-
ing the constraints for the lymph nodes.
Fig. 1. Contours for External Beam Planning. Sagittal slices showing the GTV-Tinit. (A) MRI with the expert contour. (B) MRI with contours from centres contouring on MRI. (C)
CT with contours from centres contouring on CT.
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BT planning
The first BT planning workshop had 34 participants from 11
centres, teams of MP, RO and RTT. Ten out of 11 centres submitted
their plan in time for analysis. During the workshop, the priorities
of aims and constraints for targets and OAR were the main issue.
The ‘‘standard plan” is the same for all centres, allowing to evaluate
the effect of placement of the dose points on the reported dose.
For the RVRP this resulted in a mean dose of 100 (range 80–128,
SD 15%) Gy EQD2.
For the ‘‘centre-standard plans” we found two ‘schools’ in the
Netherlands, as the ratio of the contribution of tandem/riright
ovoid/left ovoid was 60/20/20% for 5 centres and 40/30/30% for 3
centres, and 50/25/25% for one centre. One centre did not provide
a centre-standard plan.
For the optimized plans 3 centres did not achieve the minimal
planning aim doses for D90 and D98 CTVHR, D98 GTVres, and D98
CTVIR, while this should have been the highest treatment planning
priority; four centres had unnecessary high OAR doses (Figs. 3 and
S3). The spatial dose distributions differed, especially in the caudal
and cranial part (Fig. S4).
The relative contribution of tandem/ovoid/needles to the total
dose distribution differed between centres (Fig. 4). E.g. total ovoid
loading varied between 14 and 43%, needle contribution between
16 and 40%, with one exceptionally varying between 7–22%.
The plans for the second round had improved DVHs (Figs. 3 and
S3). However, the doses to the vaginal points still varied consider-
ably: 3 centres failed to meet the hard constraint for the RVRP
(Fig. 3C). The contribution of tandem/ovoid/needles remained dif-
ferent (Fig. 4). The spatial dose distributions varied among centres.
E.g., the plans of 3 centres had quite remarkable differences, espe-
cially in the cranial direction, although the 85 Gy EQD2 isodose
surface volumes and DVHs were rather similar. Furthermore, vari-
ations in relative needle contribution, resulted in quite some vari-
ation with respect to position and level of high dose volumes.
Finally, an on-site conducted survey concerning the centres’
practices for BT applications and planning was performed using
an electronic voting system. This survey revealed that the majority
of centres used an IC/IS technique in most of their applications
with in more than half of the centres 3–6 needles being applied.
Discussion
To our knowledge this is the first descriptive report concerning
a National Quality Assurance Programme for state of the art cura-
tive radiotherapy for patients with LACC. The program was
intended to improve the joint efforts off all three professions
within radiotherapy for delivering comparable EBRT and BT treat-
ments throughout the country. In the Netherlands about 350
patient with LACC are treated with curative intent per year, spread
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Fig. 2. DVH values from the External Beam plans: Upper part: Volume of the PTV45 receiving 95% of the planning aim dose for the separate centres in % for the first (A) and
the second (B) External Beam Planning workshop. Lower part, the minimum dose to the ITV45 in Gy for the first (C) and the second (D) workshop. Horizontal (red) lines: hard
constraints. For A and B the soft constraint is that the values should be close to 95%. Note that not all centres submitted plans for two workshops, and that some centres
reported erroneous values. The encircled centres submitted evaluable plans for the two workshops. (For interpretation of the references to colour in this figure legend, the
reader is referred to the web version of this article.)
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over 16 centres for EBRT and 11 centres for BT, all organized within
LPRGT. Concurrent chemotherapy (or hyperthermia) is part of a
curative LACC treatment approach in the Netherlands but has not
been considered in this project.
Organising quality assurance programs like this, requires the
exchange of patient data sets, delineations, treatment plans and
dose distributions taking into account safety and privacy aspects.
This has become feasible over the last decade due to the increased
use of DICOM formats, although not easily achievable for all con-
touring and treatment planning systems. The program, including
homework exercises and live workshops for EBRT and BT contour-
ing and treatment planning was highly appreciated by all partici-
pants. Results of the participation survey were such that ‘‘good/
very good” were scored in 90–100% for all relevant questions as
e.g. on the value of issues they learned for the daily practise, the
organisation, the set-up of the workshops, and the value of the
combination of participants for the discussion. The joint effort of
explaining and discussing modern concepts for contouring and
treatment planning aims with their respective investigational
backgrounds, helped to guide the process of national change. Hav-
ing gained experience through homework exercises before partic-
ipating in workshops especially helped to achieve active and
interactive participation. Reflecting the centres own results in rela-
tion to results of other participants and expert’s opinions was valu-
able, as well as appreciating the differences between the centres in
general, such as the use of MR.
Modern radiotherapy target concepts are complex with initial
tumour targets at time of EBRT treatment planning (initial GTV,
high and low risk CTVs and ITV) and residual tumour targets at
time of BT. These targets have different levels of complexity and
ask for understanding the anatomical situations at time of diag-
noses and the situation at time of BT. Despite written guidelines
[4,5,19,21,22] and on-going fine tuning [13,23] we still see essen-
tial differences in understanding target concepts and planning
aims. In parallel, the complexity in treatment planning is increas-
ing. The quality of IMRT/VMAT plans is highly dependent on the
previously defined planning aims and the same holds true for
image guided brachytherapy plans. Furthermore, we have to deal
with complex anatomical changes during treatment asking for
individualized ITVs, improvements in daily position verification
and ‘‘plan of the day” treatment strategies.
Education through ESTRO and ASTRO teaching courses and
workshops on national and international level intend to globally
improve understanding and conformity of these concepts. Efforts
as described for dummy run experiences within international stud-
ies like EMBRACE I [24] show that international agreement needs
guidance but is achievable. The Dutch effort for LACC radiotherapy
presented here supports this impression. Centres participating in
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Fig. 3. DVH values from the brachy plans for the separate centres: D90 CTVHR, D98 GTVres and D2cm3 sigmoid of the first plan (A) and second plan (B), and dose to the Vaginal
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EMBRACE I better fulfil the BT contouring demands compared to
centres not having this experience. Dutch BT centres participating
in EMBRACE I had to adopt GEC-ESTRO gyn BT guidelines 7 years
ago and have been using them in clinical routine since then.
In the first round, achieving acceptable EBRT plans was difficult
due to the novelty of the concepts. In the second round, institutes
already using the new concepts clinically showed considerable
improvement. Since most centres are willing to adopt these new
concepts, it is to be expected that these results will improve overall
as well. An important observation was that DVH parameters do not
tell the whole story for treatment plan evaluation. Awareness for
spatial dose distribution differences is also important and will help
fine -tuning treatment planning results. A measure for globally
judging the quality of a treatment plan is the conformity index,
but checking dose distributions visually still helps to identify dose
regions where improvements in terms of target or organ dose
might be preferable and feasible (Fig. S2).
At the moment of writing 8 Dutch centres have passed QA
requirements and dummy run procedures for EBRT and BT con-
touring and treatment planning, are on their way to entering
patients into the EMBRACE II data base. This will help strengthen
clinical evidence for modern LACC radiotherapy concepts.
Within the Dutch LPRGT it is felt that guidelines based on inter-
national consensus and repeated training help in developing a
common sense necessary for making appropriate choices in the
currently developing complexity. Organizing this sort of training
and cooperation on a national level was time and resource con-
suming but helped to accomplish better treatment conformity
among the treating centres.
Conclusion
Current LACC radiotherapy concepts for EBRT and BT target con-
touring and treatment planning are highly complex. Efforts as pre-
sented here for the ‘‘Dutch Quality Improvement Project” help to
achieve more conformity among centres. The concept including
homework and workshop activities provides a suitable platform
for discussion, exchange of experience and improvement of confor-
mity over time and is highly appreciated by all participating
centres.
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Appendix A
Glossary
GTV-Tinit Initial Gross Tumour Volume of the primary
Tumour
CTV-T-HRinit Initial High Risk Clinical Target Volume of the
primary Tumour
CTV-T-LRinit Initial Low Risk Clinical Target Volume of the
primary Tumour
ITV-T-LRinit Initial Internal Target Volume of the primary
Tumour
GTV-N Gross Tumour Volume of a individual
pahtologic lymph Node
CTV-N Clinical Target Volume of a individual
pahtologic lymph Node
PTV-N Planning Target Volume of a individual
pahtologic lymph Node
CTV-E Clinical Target Volume of the elective nodal
region, including pathological lymph nodes if
present
ITV45 ITV-T-LR + CTV-E for 45 Gy
PTV45 Planning Target Volume for 45 Gy
GTVres Residual Gross Tumour Volume of the primary
Tumour
CTVHR Adaptive Hight Risk Clinical Target Volume of
the primary Tumour
CTVIR Intermediate Risk Clinical Target Volume of the
primary Tumour
Appendix B. Participating centres
AMC Amsterdam, Catharina Ziekenhuis Eindhoven, Erasmus MC
Rotterdam, Isala Zwolle, LUMC Leiden, MAASTRO Maastricht, Med-
isch Spectrum Twente Enschede, Netherlands Cancer Institute
Amsterdam, Radboudumc Nijmegen, Radiotherapiegroep Arnhem,
Radiotherapiegroep Deventer, RIF Leeuwarden, UMC Groningen,
UMC Utrecht, ISALA Zwolle, Haaglanden MC Den Haag, all in The
Netherlands.
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